Arcus Biosciences, Inc.
Arcus Biosciences, Inc. (NASDAQ: RCUS) is a late clinical-stage biopharmaceutical company focused on developing differentiated small-molecule therapies for patients with cancer and inflammatory and autoimmune diseases. The company's website is www.arcusbio.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Arcus Biosciences, Inc. does
In the company’s own words
Arcus Biosciences, Inc. (NASDAQ: RCUS) is a late clinical-stage biopharmaceutical company focused on developing differentiated small-molecule therapies for patients with cancer and inflammatory and autoimmune diseases. The company's website is www.arcusbio.com.
Arcus maintains a robust pipeline of investigational products across oncology and inflammation programs. In oncology, the company's most advanced candidate is casdatifan, an oral HIF-2α inhibitor designed to treat clear cell renal cell carcinoma. The company has completed enrollment in its Phase 1/1b ARC-20 study and is advancing two Phase 3 registrational trials, including PEAK-1 evaluating casdatifan combined with cabozantinib in previously treated ccRCC patients, and a planned first-line study targeting a TKI-free regimen. Quemliclustat, a small-molecule CD73 inhibitor, is being evaluated in the PRISM-1 Phase 3 study for metastatic pancreatic cancer in combination with standard chemotherapy. The company also develops domvanalimab, an anti-TIGIT antibody, and zimberelimab, an anti-PD-1 antibody, both being evaluated in multiple Phase 3 oncology trials.
The inflammation portfolio comprises five research and preclinical programs targeting MRGPRX2, TNF, CCR6, CD89, and CD40 ligand, with the company expecting to advance its first development candidate into clinical trials in 2026. The MRGPRX2 antagonist program represents the most advanced inflammation effort, with potential applications in chronic spontaneous urticaria and atopic dermatitis.
Arcus operates through strategic collaborations with major pharmaceutical partners. Under its Gilead Collaboration Agreement, Gilead Sciences holds exclusive licenses to develop and commercialize certain programs globally, with Arcus retaining co-promotion rights in the United States for select candidates. Taiho Pharmaceutical holds exclusive commercialization rights in Japan and certain Asian territories. The company also maintains licensing agreements with WuXi Biologics for anti-PD-1 development and Abmuno Therapeutics for anti-TIGIT antibody programs.
The company relies on third-party contract manufacturers for production of active pharmaceutical ingredients and drug products, maintaining a capital-efficient operational model focused on research and development activities.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- HAYWARD, CA
- Fiscal year end
- December
- CIK
- 1724521
- SIC
- 2834
Financial performance, year by year
Fiscal 2018–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Arcus Biosciences, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Arcus Biosciences, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Arcus Biosciences, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Arcus Biosciences, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Arcus Biosciences, Inc.'s last four quarterly filings that the numbers alone won't show?”